SB-31

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameSB-31
Drug Alias NameSB-31
ClassificationSmall moleculesNatural product/Extract
Mechanisms of ActionUpdating
TargetsNot applicable
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSb
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSbpharmaceutical Ind.Co Ltd
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungCarcinoma, Hepatocellular

Other Information

ATC CodeN/A
Related LinksN/A